Investigating a new way of treating poor-prognosis rhabdomyosarcoma
Evaluating a novel protein methyltransferase inhibitor for poor-prognosis rhabdomyosarcoma therapy
Predicting high-risk rhabdomyosarcoma at diagnosis to improve outcomes
Assessing rhabdomyosarcoma risk prediction markers based on the biological conditions in the tumour, like low oxygen levels, few blood vessels, and genetics.
Investigating the shape of fusion genes in rhabdomyosarcoma
How the 3D shape of fusion gene genetic code affects cancer cell behaviour and whether shape-modifying medicines could mitigate these effects.
Discovering what makes teenagers and young adults with soft tissue sarcomas different
Finding the biological differences between teenage and young adult cancers cells compared to older adults.
Liquid biopsies for rhabdomyosarcoma: A new way to improve rhabdomyosarcoma treatment
Looking for differences in newly diagnosed RMS patient samples to see if there are any that could be used to show whether treatments are working.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
New treatments for relapsed rhabdomyosarcoma
Developing better models of rhabdomyosarcoma to test available treatments.
A molecular approach to predict recurrence or spread of cancer that will lead to improving outcomes for children with rhabdomyosarcoma
MG-fnRMS and CINSARC gene expression signatures to predict relapse in fusion gene negative rhabdomyosarcomas: assessing an approach to improve patient outcomes
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma